Precigen, Inc. (PGEN) — SEC Filings
Precigen, Inc. (PGEN) — 41 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 24 8-K, 6 10-Q, 2 10-K/A.
View Precigen, Inc. on SEC EDGAR
Overview
Precigen, Inc. (PGEN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Precigen, Inc. reported a significant increase in net loss, reaching $(227.1) million for the nine months ended September 30, 2025, compared to $(106.5) million for the same period in 2024. This substantial increase was primarily driven by a $(139.5) million change in the fair value of warrant liabi
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 3 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Precigen, Inc. is neutral.
Filing Type Overview
Precigen, Inc. (PGEN) has filed 6 10-Q, 24 8-K, 1 DEFA14A, 2 10-K/A, 2 10-K, 2 SC 13D/A, 1 DEF 14A, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of PGEN's 36 recent filings, 3 were flagged as high-risk, 19 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $5.1M |
| Net Income | $(227.1)M |
| EPS | $(1.36) |
| Debt-to-Equity | 2.22 |
| Cash Position | $14.3M |
| Operating Margin | N/A |
| Total Assets | $171.3M |
| Total Debt | $92.9M |
Key Executives
- Dr. Helen B. Torley
- Dr. Alan D. Sauer
- Dr. Helen B. Ribar
- Dr. Robert J. Hariri
- Randal J. Kirk
- Dr. Helen R. Ribes
- Dr. David L. R. Gordon
- R. J. Kirk
- Helen Sabzevari
Industry Context
Precigen operates in the biotechnology sector, characterized by high R&D investment, long development cycles, and significant regulatory hurdles. The industry is competitive, with companies focusing on novel therapies and platform technologies. Recent trends include increased collaboration and licensing deals as a means to fund development and access new markets, alongside a growing reliance on external financing and strategic partnerships.
Top Tags
financials (5) · 10-Q (5) · corporate-governance (5) · financial-reporting (5) · material-definitive-agreement (4) · 8-k (4) · 8-K (3) · SEC Filing (3) · pharmaceuticals (3) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $(227.1)M | Increased from $(106.5)M in 2024, primarily due to warrant liabilities and preferred stock deemed dividend. |
| Total Revenues | $5.1M | Increased from $2.7M in 2024, driven by new collaboration and licensing revenue. |
| Change in Fair Value of Warrant Liabilities | $139.5M | Significant non-cash expense contributing to the net loss. |
| Deemed Dividend on Preferred Stock | $179.0M | Non-cash expense impacting net loss attributable to common shareholders. |
| Cash and Cash Equivalents | $14.3M | Decreased from $29.5M at December 31, 2024, indicating reduced liquidity. |
| Long-term Debt | $92.8M | Increased from zero, representing a new significant financial obligation. |
| Research and Development Expenses | $34.3M | Decreased from $41.3M in 2024, showing a shift in operational spending. |
| Selling, General and Administrative Expenses | $52.4M | Increased from $30.2M in 2024, indicating higher overhead costs. |
| Common Shares Outstanding | 353,810,556 | Increased from 292,869,097 at December 31, 2024, due to preferred stock conversion and other issuances. |
| Net Loss Per Share | $(1.36) | Increased from $(0.41) in 2024, reflecting the larger net loss and increased share count. |
| Commission File Number | 001-36042 | Precigen's SEC filing identifier |
| I.R.S. Employer Identification No. | 26-0084895 | Precigen's tax identification number |
| Total Revenue (Q2 2025) | $1.2M | Decreased 42.9% from $2.1M in Q2 2024 |
| Total Revenue (YTD 2025) | $2.4M | Decreased 41.5% from $4.1M in YTD 2024 |
| Quarterly Revenue Decrease | 42.9% | Significant year-over-year decline for Q2 2025 |
Forward-Looking Statements
- {"claim":"Precigen's stock (PGEN) may experience short-term volatility due to leadership uncertainty.","entity":"PGEN","targetDate":"2024-03-31","confidence":"medium"}
- {"claim":"Precigen will announce a new CEO or interim CEO by the end of Q1 2024.","entity":"Precigen, Inc.","targetDate":"2024-03-31","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Precigen, Inc. (PGEN)?
Precigen, Inc. has 41 recent SEC filings from Jan 2024 to Nov 2025, including 24 8-K, 6 10-Q, 2 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PGEN filings?
Across 41 filings, the sentiment breakdown is: 3 bearish, 37 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Precigen, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Precigen, Inc. (PGEN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Precigen, Inc.?
Key financial highlights from Precigen, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PGEN?
The investment thesis for PGEN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Precigen, Inc.?
Key executives identified across Precigen, Inc.'s filings include Dr. Helen B. Torley, Dr. Alan D. Sauer, Dr. Helen B. Ribar, Dr. Robert J. Hariri, Randal J. Kirk and 4 others.
What are the main risk factors for Precigen, Inc. stock?
Of PGEN's 36 assessed filings, 3 were flagged high-risk, 19 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Precigen, Inc.?
Recent forward-looking statements from Precigen, Inc. include guidance on {"claim":"Precigen's stock (PGEN) may experience short-term volatility due to leadership uncertainty.","entity":"PGEN"," and 1 other predictions.